Dr. Silver Talks About Advances in Treatment of Hematological Cancers

Joel Silver, MD
Published: Friday, Nov 16, 2018



Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Incremental steps have been taken in to improve on therapy in this field. For example, says Silver, in the past few years new therapies have been approved in multiple myeloma. There is now a better understanding of the disease based on the discovery of new biomarkers and advances in cytogenetics. In addition, there are better ways of assessing which patients are more likely to have progression of disease with standard therapy. Over the past 5 years, sequencing of drugs has improved, and physicians know better how to determine who needs aggressive therapy such as stem cell transplant.
SELECTED
LANGUAGE


Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Incremental steps have been taken in to improve on therapy in this field. For example, says Silver, in the past few years new therapies have been approved in multiple myeloma. There is now a better understanding of the disease based on the discovery of new biomarkers and advances in cytogenetics. In addition, there are better ways of assessing which patients are more likely to have progression of disease with standard therapy. Over the past 5 years, sequencing of drugs has improved, and physicians know better how to determine who needs aggressive therapy such as stem cell transplant.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x